Search Results for "corticosteroids, injectable"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for corticosteroids, injectable. Results 51 to 60 of 97 total matches.
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
.
Patients were randomized 2:1 to receive anakinra
100 mg or placebo injected subcutaneously once
daily ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
OTC Primatene Mist Returns
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019 (Issue 1564)
and
heart rate.
Misuse or abuse of the product by excessive inhalation
or IV injection of epinephrine ...
The FDA has approved over-the-counter (OTC) sale
of inhaled epinephrine (Primatene Mist – Amphastar),
a nonselective alpha and beta agonist, for temporary
relief of mild symptoms of intermittent asthma in
patients ≥12 years old who have been diagnosed with
mild intermittent asthma by a healthcare professional.
The original version of Primatene Mist, which was
approved by the FDA in 1967, was removed from the
market in 2011 because the metered-dose inhaler (MDI)
contained ozone-depleting chlorofluorocarbon (CFC)
propellants; the new MDI contains hydrofluoroalkane
(HFA)...
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
) and upadacitinib
(Rinvoq) can be used when first-line drugs are
ineffective or not tolerated. Corticosteroids can ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
.
CORTICOSTEROIDS — When only a few joints are
involved, intra-articular injections of corticosteroids
may provide ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
(frequency ≥20%)
of teclistamab in MajesTEC-1 were pyrexia, musculoskeletal
pain, injection-site reactions ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on response rate. Teclistamab is the first
bispecific BCMA-directed CD3 T-cell engager to be
approved in the US.
Colchicine and Other Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009 (Issue 1326)
aspiration of joint fluid and injection of a corticosteroid such as methylprednisolone or triamcinolone ...
Until the recent introduction of febuxostat (Uloric), no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid (Colbenemid, and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
, musculoskeletal pain, injection-site
reactions, pyrexia, and abdominal pain can
occur. Neurologic toxicity ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
. Injection of voretigene neparvovecrzyl
into the subretinal space can potentially restore
the visual cycle ...
The FDA has approved voretigene neparvovec-rzyl
intraocular suspension (Luxturna – Spark), an
adeno-associated virus vector-based gene therapy,
for treatment of confirmed biallelic RPE65 mutation-associated
retinal dystrophy in patients who have viable
retinal cells. It is the first gene replacement therapy
approved in the US that targets a disease caused by
mutations in a specific gene and the first pharmacologic
treatment to be approved for this disorder.
Three New Drugs for Hereditary Angioedema
The Medical Letter on Drugs and Therapeutics • Aug 23, 2010 (Issue 1345)
and sites; can be 4 and 24 hrs3,4 pyrexia, injection site
suppresses bradykinin repeated if reactions ...
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary
angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016 (Issue 1490)
injection of a
corticosteroid is a reasonable alternative. Opioids can
be used as a last resort ...
The FDA has approved Vivlodex (Iroko), a low-dose
formulation of the nonsteroidal anti-inflammatory drug
meloxicam (Mobic, and generics), for management of
osteoarthritis pain. According to the manufacturer, the
new formulation aligns with stronger FDA warnings
about the cardiovascular risks of NSAIDs and the
recommendation to use the lowest possible doses of
these drugs.